Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
With
University Medical Center Goettingen
German Federal Ministry of Education and Research
Age
2–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Definitive diagnosis of Alport syndrome: Kidney biopsy (patient or affected relative/s), and/or mutation analysis (hemizygous X-chromosomal or homozygous autosomal-recessive) and assessment of criteria for clinical diagnosis (haematuria, positive family history regarding kidney diseases, ocular changes, labyrinthine hearing loss)
Alport syndrome levels 0, I or II at screening (microhaematuria without microalbuminuria or microalbuminuria \[30-300 mg albumin/gCrea\]) or proteinuria \>300 mg albumin/gCrea with GFR\>80ml/min). Patients with Alport stage II are not subject to randomization but are treated opel label.
Aged between ≥24 months and \<18 years at screening
Assent from patient and informed consent from parents/legal guardian
You may not be if
Uncertain diagnosis or variants of Alport syndrome such as a heterozygous carrier
Alport syndrome levels III, or IV (albuminuria \>300 mg/g Crea, creatinine clearance \<60 mL/min, or end stage renal failure \[ESRF\])
Known allergies or intolerances to ramipril or related compounds
Known contraindication for ACEi-therapy
Additional chronic renal, pulmonary or cardiac diseases
